Attach to Form 990 or Form 990-EZ.
Information about Schedule A (Form 990 or 990-EZ) and its instructions is at www.irs.gov/form990.
| (i)Name of supported organization | (ii) EIN | (iii) Type of organization (described on lines 1- 9 above (see instructions)) | (iv) Is the organization listed in your governing document? | (v) Amount of monetary support (see instructions) | (vi) Amount of other support (see instructions) | |
|---|---|---|---|---|---|---|
| Yes | No | |||||
| Total | ||||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2011 | (b) 2012 | (c) 2013 | (d) 2014 | (e) 2015 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any unusual grants.) .... | 41,644,804 | 67,271,113 | 74,310,661 | 91,256,682 | 89,944,366 | 364,427,626 |
| 2 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf....... | 0 | |||||
| 3 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | 0 | |||||
| 4 | Total. Add lines 1 through 3 | 41,644,804 | 67,271,113 | 74,310,661 | 91,256,682 | 89,944,366 | 364,427,626 |
| 5 | The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f).. | 34,266,731 | |||||
| 6 | Public support. Subtract line 5 from line 4. | 330,160,895 | |||||
Calendar year
(or fiscal year beginning in) ![]() |
(a) 2011 | (b) 2012 | (c) 2013 | (d) 2014 | (e) 2015 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 7 | Amounts from line 4.. | 41,644,804 | 67,271,113 | 74,310,661 | 91,256,682 | 89,944,366 | 364,427,626 |
| 8 | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources... | 2,311,932 | 2,888,204 | 7,196,139 | 10,415,818 | 8,960,634 | 31,772,727 |
| 9 | Net income from unrelated business activities, whether or not the business is regularly carried on.. | ||||||
| 10 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.).. | 220,423 | 225,566 | 255,201 | 164,499 | 448,890 | 1,314,579 |
| 11 | Total support. Add lines 7 through 10. | 397,552,045 | |||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2011 | (b) 2012 | (c) 2013 | (d) 2014 | (e) 2015 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") . | ||||||
| 2 | Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose...... | ||||||
| 3 | Gross receipts from activities that are not an unrelated trade or business under section 513... | ||||||
| 4 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf... | ||||||
| 5 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | ||||||
| 6 | Total. Add lines 1 through 5. | ||||||
| 7a | Amounts included on lines 1, 2, and 3 received from disqualified persons... | ||||||
| b | Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year. | ||||||
| c | Add lines 7a and 7b.. | ||||||
| 8 | Public support. (Subtract line 7c from line 6.) | ||||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2011 | (b) 2012 | (c) 2013 | (d) 2014 | (e) 2015 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 9 | Amounts from line 6... | ||||||
| 10a | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources.. | ||||||
| b | Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975. | ||||||
| c | Add lines 10a and 10b. | ||||||
| 11 | Net income from unrelated business activities not included in line 10b, whether or not the business is regularly carried on. | ||||||
| 12 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.) .. | ||||||
| 13 | Total support. (Add lines 9, 10c, 11, and 12.).. | ||||||
| Section A - Adjusted Net Income | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Net short-term capital gain | 1 | ||||
| 2 | Recoveries of prior-year distributions | 2 | ||||
| 3 | Other gross income (see instructions) | 3 | ||||
| 4 | Add lines 1 through 3 | 4 | ||||
| 5 | Depreciation and depletion | 5 | ||||
| 6 | Portion of operating expenses paid or incurred for production or collection of gross income or for management, conservation, or maintenance of property held for production of income (see instructions) | 6 | ||||
| 7 | Other expenses (see instructions) | 7 | ||||
| 8 | Adjusted Net Income (subtract lines 5, 6 and 7 from line 4) | 8 | ||||
| Section B - Minimum Asset Amount | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Aggregate fair market value of all non-exempt-use assets (see instructions for short tax year or assets held for part of year): | 1 | ||||
| a | Average monthly value of securities | 1a | ||||
| b | Average monthly cash balances | 1b | ||||
| c | Fair market value of other non-exempt-use assets | 1c | ||||
| d | Total (add lines 1a, 1b, and 1c) | 1d | ||||
| e |
Discount claimed for blockage or other factors (explain in detail in Part VI): |
|||||
| 2 | Acquisition indebtedness applicable to non-exempt use assets | 2 | ||||
| 3 | Subtract line 2 from line 1d | 3 | ||||
| 4 | Cash deemed held for exempt use. Enter 1-1/2% of line 3 (for greater amount, see instructions). | 4 | ||||
| 5 | Net value of non-exempt-use assets (subtract line 4 from line 3) | 5 | ||||
| 6 | Multiply line 5 by .035 | 6 | ||||
| 7 | Recoveries of prior-year distributions | 7 | ||||
| 8 | Minimum Asset Amount (add line 7 to line 6) | 8 | ||||
| Section C - Distributable Amount | Current Year | |||||
| 1 | Adjusted net income for prior year (from Section A, line 8, Column A) | 1 | ||||
| 2 | Enter 85% of line 1 | 2 | ||||
| 3 | Minimum asset amount for prior year (from Section B, line 8, Column A) | 3 | ||||
| 4 | Enter greater of line 2 or line 3 | 4 | ||||
| 5 | Income tax imposed in prior year | 5 | ||||
| 6 | Distributable Amount. Subtract line 5 from line 4, unless subject to emergency temporary reduction (see instructions) | 6 | ||||
| Section D - Distributions | Current Year | |
|---|---|---|
| 1 Amounts paid to supported organizations to accomplish exempt purposes | ||
|
2
Amounts paid to perform activity that directly furthers exempt purposes of supported organizations, in excess of income from activity |
||
| 3 Administrative expenses paid to accomplish exempt purposes of supported organizations | ||
| 4 Amounts paid to acquire exempt-use assets | ||
| 5 Qualified set-aside amounts (prior IRS approval required) | ||
| 6 Other distributions (describe in Part VI). See instructions | ||
| 7Total annual distributions. Add lines 1 through 6. | ||
|
8
Distributions to attentive supported organizations to which the organization is responsive (provide details in Part VI). See instructions |
||
| 9 Distributable amount for 2015 from Section C, line 6 | ||
| 10 Line 8 amount divided by Line 9 amount | ||
| Section E - Distribution Allocations (see instructions) |
(i) Excess Distributions |
(ii) Underdistributions Pre-2015 |
(iii) Distributable Amount for 2015 |
|
|---|---|---|---|---|
|
1
Distributable amount for 2015 from Section C, line 6 |
||||
|
2
Underdistributions, if any, for years prior to 2015 (reasonable cause required--see instructions) |
||||
| 3 Excess distributions carryover, if any, to 2015: | ||||
| a | ||||
| b | ||||
| c | ||||
| d From 2013....... | ||||
| e From 2014....... | ||||
| fTotal of lines 3a through e | ||||
| g Applied to underdistributions of prior years | ||||
| h Applied to 2015 distributable amount | ||||
|
i
Carryover from 2010 not applied (see instructions) |
||||
| j Remainder. Subtract lines 3g, 3h, and 3i from 3f. | ||||
| 4Distributions for 2015 from Section D, line 7: | ||||
| $ | ||||
| a Applied to underdistributions of prior years | ||||
| b Applied to 2015 distributable amount | ||||
| c Remainder. Subtract lines 4a and 4b from 4. | ||||
|
5
Remaining underdistributions for years prior to 2015, if any. Subtract lines 3g and 4a from line 2 (if amount greater than zero, see instructions) |
||||
|
6
Remaining underdistributions for 2015. Subtract lines 3h and 4b from line 1 (if amount greater than zero, see instructions) |
||||
|
7 Excess distributions carryover to 2016. Add lines 3j and 4c. |
||||
| 8 Breakdown of line 7: | ||||
| a | ||||
| b | ||||
| c Excess from 2013....... | ||||
| d From 2014....... | ||||
| e From 2015....... | ||||
| Facts And Circumstances Test |
|---|
| Return Reference | Explanation |
|---|
| Software ID: | |
| Software Version: |
Attach to Form 990 or 990-EZ.
Information about Schedule O (Form 990 or 990-EZ) and its instructions is at| Return Reference | Explanation |
|---|---|
| ORGANIZATION'S MISSION | FORM 990, PART III, LINE 1 THE MISSION OF THE LABORATORY IS TO DISCOVER PRECISE GENOMIC SOLUTIONS FOR DISEASE AND EMPOWER THE GLOBAL BIOMEDICAL COMMUNITY IN THE SHARED QUEST TO IMPROVE HUMAN HEALTH. TO ACCOMPLISH THIS MISSION, THE LABORATORY: 1) CONDUCTS BASIC BIOMEDICAL RESEARCH TO INCREASE THE KNOWLEDGE OF DEVELOPMENT, GROWTH, REPRODUCTION, PHYSIOLOGY, AND PATHOPHYSIOLOGY THROUGH RESEARCH WITH GENETICALLY DEFINED EXPERIMENTAL MOUSE MODELS AND OTHER MODELS OF DISEASE; 2) CONDUCTS TRANSLATIONAL BIOMEDICAL RESEARCH TO IDENTIFY THE GENOMIC IMPACT ON HUMAN DISEASE, PROMOTE THE ESTABLISHMENT OF MORE PRECISE, TARGETED THERAPIES, OFFER CUTTING EDGE GENOMIC DIAGNOSTICS TO IMPROVE PATIENT CARE, AND PROVIDE ADVANCED COMPUTATIONAL TOOLS, DATABASES AND KNOWLEDGE MANAGEMENT SYSTEMS TO THE BIOMEDICAL RESEARCH AND MEDICAL COMMUNITIES; 3) TRAINS AND EDUCATES STUDENTS, SCIENTISTS, PHYSICIANS, AND OTHER PROFESSIONALS IN THESE AREAS; AND 4) PROMOTES SCIENTIFIC DISCOVERY THROUGH THE PROVISION OF MOUSE MODELS AND OTHER MODELS OF HUMAN DISEASE AND THE PROVISION OF RESEARCH, CLINICAL, COMPUTATIONAL AND INFORMATION SERVICES TO THE GLOBAL SCIENTIFIC AND MEDICAL COMMUNITIES. |
| PROGRAM SERVICES | FORM 990, PART III, LINE 4A-4C DEVELOP AND PROVIDE GENETIC RESOURCES THE JACKSON LABORATORY MOUSE REPOSITORY, PRODUCTION AND RESEARCH SERVICES ARE INCLUDED AMONG THE PREMIER RESOURCES AVAILABLE TO BIOMEDICAL RESEARCHERS. IN 2015, OVER 130 COMMON LABORATORY STRAINS AS WELL AS THOUSANDS OF SELECT MUTANT AND GENETICALLY MODIFIED STRAINS OF JAX MICE WERE DISTRIBUTED TO OVER 10,000 INVESTIGATORS IN MORE THAN 1,300 INSTITUTIONS IN AT LEAST 60 COUNTRIES. DISTRIBUTION OF THESE STRAINS SUPPORTS RESEARCHERS SEEKING CURES FOR THE WORLDS MOST PREVALENT HUMAN DISEASES AND HELPS SHRINK THE TIMELINE REQUIRED TO BRING NEW THERAPIES TO PATIENTS IN NEED. THE JACKSON LABORATORY MOUSE REPOSITORY, PRODUCTION AND RESEARCH SERVICES COLLECTS DATA CONCERNING THE BREEDING, HUSBANDRY, MAINTENANCE AND DEVELOPMENT OF MOUSE MODELS THAT BECOMES PART OF THE REPOSITORY OF KNOWLEDGE AND IS SHARED WITH THE GLOBAL MOUSE RESEARCH AND BIOMEDICAL COMMUNITY TO FOSTER ETHICAL, INFORMED USE OF THESE ANIMALS IN SCIENTIFIC DISCOVERY. IN 2015 THIS DATA WAS SHARED IN OVER 150 EDUCATIONAL SEMINARS, ATTENDED BY OVER 10,000 RESEARCHERS. DATA FROM THE JACKSON LABORATORYS MOUSE DEVELOPMENT RESEARCH IS ALSO SHARED VIA PEER REVIEWED PUBLICATIONS AND PUBLICLY ACCESSIBLE DATABASES. THESE INCLUDE THE MOUSE PHENOME DATABASE (MPD) AND THE MOUSE TUMOR BIOLOGY (MTB) DATABASE. NEW IN 2015, GENOMICS, GENE EXPRESSION, AND GENE VARIANT DATA FROM OVER 100 CLINICALLY RELEVANT PATIENT DERIVED XENOGRAFT (PDX) MOUSE MODELS AND DRUG EFFICACY DATA FROM TEN OF THESE HUMAN TUMOR PDX MODELS WERE CONTRIBUTED TO THE MTB DATABASE. INFORMATION CONTRIBUTED TO MTB AS WELL AS MPD INFORMS APPROPRIATE MODEL SELECTION FOR PRECISE PRECLINICAL RESEARCH APPLICATIONS THAT CONTRIBUTES TO DRUG DEVELOPMENT PROGRAMS. TO BETTER UNDERSTAND THE ROLE OF THE HUMAN IMMUNE SYSTEM IN DISEASES SUCH AS CANCER, THE JACKSON LABORATORY DEVELOPED THE NEW HUMANIZED NSG-SGM3 MODEL. THROUGH THE JACKSON LABORATORYS EDUCATIONAL OUTREACH, THIS MODEL HAS BEGUN TO BE READILY ACCESSED IN 2015 BY RESEARCHERS AND DRUG DEVELOPMENT SCIENTISTS WHO SEEK TO UNDERSTAND HOW THE HUMAN IMMUNE SYSTEM INTERACTS WITH HUMAN TUMORS IN THE CONTEXT OF A SMALL ANIMAL MODEL. THE JACKSON LABORATORY, THE UNIVERSITY OF CALIFORNIA DAVIS AND OTHER CANCER HOSPITALS ARE CONTINUING TO PARTNER TO BUILD THE PRIMARY HUMAN TUMORS CONSORTIUM, A PUBLICLY AVAILABLE LIBRARY OF PRIMARY HUMAN TUMORS FOR RESEARCH AND DRUG DEVELOPMENT. BY JOINING THE CONSORTIUM, MEMBERS WILL CONTRIBUTE TO AND SHARE IN A TUMOR LIBRARY THAT WILL VASTLY EXCEED WHAT ANY ONE INSTITUTION COULD BUILD ON ITS OWN. THIS SHARED RESOURCE ULTIMATELY WILL GREATLY EXPAND RESEARCH CAPACITY FOR ALL CONSORTIUM PARTNERS WHILE PRESERVING VARIED AND VALUABLE TUMORS FOR FUTURE RESEARCH. THE JACKSON LABORATORY NOW HAS ESTABLISHED GREATER THAN 350 MODELS THAT ARE READILY AVAILABLE BEYOND THE CONSORTIUM PARTNERS. THE GENOMICS DATA IS ALSO PROVIDED TO ANYONE IN THE BROADER SCIENTIFIC COMMUNITY ON REQUEST. THE JACKSON LABORATORY FOR GENOMIC MEDICINE HAS PARTNERED WITH EASTERN MAINE COMMUNITY HOSPITAL TO ESTABLISH A CLINICAL OBSERVATION STUDY THAT PROSPECTIVELY TRACKS 25 CANCER PATIENTS THROUGH THEIR TREATMENT STRATEGIES. THIS JAX-FUNDED STUDY WILL RESEARCH THE UTILITY OF THE JAX CANCER TREATMENT PROFILE GENOMIC DIAGNOSTIC ASSAY AND UNDERSTAND THE IMPACT ON PATIENT OUTCOME. EDUCATION AND TRAINING IN 2015 A NEW, ONLINE JACKSON LABORATORY CONTINUING MEDICAL EDUCATION (CME) PROGRAM WAS DESIGNED AND OFFERED FOR PHYSICIANS TO BETTER PREPARE PATIENTS FOR CANCER GENETIC TESTING. FOR PATIENTS AT HIGH RISK FOR HAVING A HEREDITARY CANCER SYNDROME, GENETIC TESTING MAY BE APPROPRIATE. PRE-TEST DECISIONS & COUNSELING FOCUSES ON THE BENEFITS AND LIMITATIONS OF TESTING, AND PROVIDES THE OPPORTUNITY TO PRACTICE DECIDING WHETHER TESTING IS THE BEST CHOICE FOR A SPECIFIC PATIENT. PRE-TEST DECISIONS & COUNSELING IS THE FIRST IN A SERIES OF FREE, ONLINE CME PROGRAMS ON CANCER GENETIC TESTING THAT THE JACKSON LABORATORY WILL OFFER. SUPPORTED BY EDUCATIONAL GRANTS FROM THE MAINE CANCER FOUNDATION AND THE JACKSON LABORATORY DIRECTORS INNOVATION FUND, THE PROGRAM JOINS THE LABORATORYS GROWING ROSTER OF CONTINUING EDUCATION PROGRAMS DESIGNED TO HELP HEALTH CARE PROVIDERS INTEGRATE GENETICS AND GENOMICS INTO CLINICAL CARE. THE JACKSON LABORATORY FOR GENOMIC MEDICINE BECAME A PARTNER WITH THE CONNECTICUT STATE UNIVERSITY SYSTEM IN THE GENOMICS WORKFORCE CONSORTIUM, AN INITIATIVE TO HELP STUDENTS ACQUIRE THE KNOWLEDGE AND SKILLS NEEDED TO COMPETE FOR JOBS IN THE STATES BIOSCIENCES SECTOR. JAX ALSO HOSTED THE SECOND BIOSCIENCE CAREERS FORUM, WHERE INDUSTRY LEADERS ADVISED CONNECTICUT STUDENTS ON PREPARING FOR THEIR FUTURE PROFESSIONS. JACKSON LABORATORY OFFICIALS AND SCIENTISTS VISITED EWHA WOMANS UNIVERSITY IN SEOUL, SOUTH KOREA, FOR AN INTERNATIONAL JOINT SYMPOSIUM ON GENOMIC MEDICINE AS THE FIRST STEP IN DEVELOPING COOPERATIVE INITIATIVES IN GENOMICS-BASED MEDICAL RESEARCH. "TEACHING THE GENOME GENERATION" WAS A NEW PROGRAM INTRODUCED IN 2015. IT IS AN INNOVATIVE PROGRAM TO GIVE HIGH SCHOOL SCIENCE AND MATH TEACHERS THE TOOLS TO TEACH GENETICS AND GENOMICS THROUGH THE LENS OF PERSONALIZED MEDICINE. IN COURSES PRESENTED AT JAX CAMPUSES IN BAR HARBOR, MAINE, AND FARMINGTON, CONN., PARTICIPANTS CONDUCTED CLASSROOM EXPERIMENTS, COLLECTED AND ANALYZED REAL DATA, AND DISCUSSED THE ETHICAL COMPLEXITIES OF RESEARCH. BIOMEDICAL RESEARCH THE NATIONAL INSTITUTE ON AGING ANNOUNCED A GRANT OF $3.6 MILLION TO JAX ASSISTANT PROFESSOR GARETH HOWELL, PH.D., AND HARVARD UNIVERSITY ASSISTANT PROFESSOR BETH STEVENS, PH.D., FOR RESEARCH IN MECHANISMS OF ALZHEIMERS DISEASE. THE HOWELL LAB IS STUDYING CERTAIN CELLS THAT ARE PART OF THE IMMUNE SYSTEMS COMPLEMENT CASCADE. KNOWN AS COMPLEMENT-EXPRESSING MYELOID CELLS, THESE CELLS APPEAR TO CAUSE SOME OF THE DAMAGE TO SYNAPSES AND BLOOD VESSELS DURING AGING AND THE EARLY STAGES OF ALZHEIMERS DISEASE. THE NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM AWARDED A $2 MILLION GRANT TO JAX ASSOCIATE PROFESSOR ELISSA CHESLER, PH.D., TO DEVELOP ONLINE RESOURCES TO AID RESEARCHERS IN THE STUDY OF GENES ASSOCIATED WITH ALCOHOLISM AND ADDICTION. CHESLERS LAB FOCUSES ON COMPUTATIONAL STRATEGIES FOR THE BEHAVIORAL NEUROSCIENCES. JAX PROFESSOR ROBERT BURGESS, PH.D., RECEIVED NEARLY $1 MILLION IN FUNDING - $162,500 FROM THE NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE AND $300,000 FROM THE MUSCULAR DYSTROPHY ASSOCIATION - FOR HIS WORK IN UNDERSTANDING THE GENETIC BASIS FOR A NEUROLOGICAL DISORDER KNOWN AS CHARCOT-MARIE-TOOTH DISEASE (CMT). CMT IS A GENETIC NEUROLOGICAL DISORDER THAT CAUSES DAMAGE TO THE PERIPHERAL NERVES, THE BUNDLES OF NERVE CELL FIBERS THAT CONNECT THE BRAIN AND SPINAL CORD TO MUSCLES AND SENSORY ORGANS. A MULTI-INSTITUTIONAL GROUP OF LEADING MICROBIOME RESEARCHERS INCLUDING JAX PROFESSOR GEORGE WEINSTOCK, PH.D., ANNOUNCED THE FORMATION OF A CONSORTIUM TO "UNDERSTAND AND HARNESS THE CAPABILITIES OF THE EARTH'S MICROBIAL ECOSYSTEMS." THE UNIFIED MICROBIOME INITIATIVE (UMI) BRINGS TOGETHER U.S.-BASED SCIENTISTS DRAWN FROM MULTIPLE DISCIPLINES AND ACROSS THE ACADEMIC, NONPROFIT AND BIOTECH SPHERES TO ACCELERATE BASIC MICROBIOME RESEARCH AND ITS TRANSLATION TO USEFUL APPLICATIONS IN MEDICINE, ENGINEERING AND BEYOND. WEINSTOCK AND COLLEAGUES AT HARVARD MEDICAL SCHOOL AND OTHER INSTITUTIONS PUBLISHED A STUDY OF THE IMPACT OF INTRAVENOUSLY ADMINISTERED ANTIBIOTICS ON THE MICROBIOMES OF NEWBORN INFANTS. JAX ASSISTANT PROFESSOR JULIA OH, PH.D., WAS THE LEAD AUTHOR OF A PAPER DEMONSTRATING THE USE OF SINGLE MOLECULE SEQUENCING TO BETTER IDENTIFY AND CHARACTERIZE THE COLONIES OF MICROORGANISMS THAT LIVE ON HUMAN SKIN. AT JAXS CENTER FOR SINGLE CELL GENOMICS, PAUL ROBSON, PH.D., DIRECTOR, AND HIS COLLEAGUES ARE SEIZING THE REMARKABLE OPPORTUNITIES IN THIS NEW FIELD IN A JOINT EFFORT WITH THE UNIVERSITY OF CONNECTICUT, INCLUDING UCONN HEALTH. FOR EXAMPLE, JAX ASSISTANT PROFESSOR MICHAEL STITZEL, PH.D., IS EXPLORING KEY QUESTIONS IN TYPE 2 DIABETES BY PROBING THE ISLET CELLS THAT RESIDE IN SMALL CLUSTERS OF THE PANCREAS. JAX SCIENTISTS ALSO PROFILED TUMORS FROM CANCER PATIENTS TO DETERMINE THEIR PRECISE CELLULAR MAKEUP. |
| FORM 990 REVIEW PROCESS | FORM 990, PART VI, SECTION B, QUESTION 11B THE AUDIT COMMITTEE OF THE JACKSON LABORATORY'S BOARD OF TRUSTEES REVIEWS A DRAFT COPY OF THE IRS FORM 990 BEFORE IT IS PROVIDED TO THE BOARD OF TRUSTEES. AFTER THE AUDIT COMMITTEE'S REVIEW, THE IRS FORM 990 IS FINALIZED AND PROVIDED TO THE BOARD OF TRUSTEES PRIOR TO FILING WITH THE INTERNAL REVENUE SERVICE. |
| CONFLICT OF INTEREST POLICY | FORM 990, PART VI, SECTION B, QUESTION 12C THE JACKSON LABORATORY PROVIDES ALL OFFICERS, BOARD MEMBERS AND KEY EMPLOYEES WITH A CONFLICT OF INTEREST, CODE OF ETHICS AND DISCLOSURE FORMS AS WELL AS THE DISTRIBUTION OF ALL POLICIES REGARDING THE CONFLICT OF INTEREST AND CODE OF ETHICS. THIS PROCESS IS DONE ANNUALLY. THE DISCLOSURE AND COMPLIANCE ATTESTATIONS ARE RETURNED TO THE GENERAL COUNSEL, WHERE THEY ARE RECORDED AND TALLIED FOR COMPLETENESS. DISCLOSURES, AS WELL AS ANY FOLLOW UP QUESTIONS, ARE ROUTED THROUGH GENERAL COUNSEL, AND IF NECESSARY THE AUDIT COMMITTEE. TRUSTEES AND EXECUTIVES WITH AN APPARENT OR ACTUAL CONFLICT OF INTEREST RECUSE THEMSELVES FROM DECISION MAKING. |
| COMPENSATION POLICY | FORM 990, PART VI, SECTION B, QUESTION 15B THE COMPENSATION AND HUMAN RESOURCES COMMITTEE OF THE BOARD OF TRUSTEES SETS COMPENSATION AND BENEFITS FOR THE CHIEF EXECUTIVE OFFICER, EXECUTIVE VICE PRESIDENT AND CHIEF OPERATING OFFICER, THE VICE PRESIDENT OF RESEARCH, THE VICE PRESIDENT OF EXTERNAL AFFAIRS AND STRATEGIC PARTNERSHIPS, THE CHIEF FINANCIAL OFFICER AND EQUIVALENT POSITIONS AS WELL AS ANY OTHER EMPLOYEES OF THE LABORATORY WHO WOULD BE CONSIDERED 'INSIDERS'DISQUALIFIED PERSONS' WITHIN THE MEANING OF THE INTERMEDIATE SANCTIONS RULES UNDER THE INTERNAL REVENUE CODE. MEMBERS OF THE COMMITTEE ARE INDEPENDENT TRUSTEES SELECTED BY THE CHAIR OF THE BOARD OF TRUSTEES. THE COMMITTEE IS GUIDED BY MARKET DATA OF COMPENSATION PACKAGES FOR SIMILAR POSITIONS IN COMPARABLE ORGANIZATIONS. MARKET DATA IS PREPARED FOR THE COMMITTEE BY AN EXTERNAL EXECUTIVE COMPENSATION FIRM WHICH CONSIDERS COMPENSATION INFORMATION REPORTED IN FORM 990'S OF COMPARABLE ORGANIZATIONS AND THE RESULTS OF RECOGNIZED COMPENSATION SURVEYS. THE SENIOR DIRECTOR OF HUMAN RESOURCES IS AVAILABLE TO THE COMMITTEE TO PROVIDE ANY OTHER DATA NEEDED. THE CEO MEETS WITH THE COMMITTEE AT LEAST ANNUALLY TO PROVIDE THE COMMITTEE MEMBERS WITH ANNUAL PERFORMANCE REVIEWS OF HIS REPORTS. THE COMMITTEE'S REVIEW PROCESS AND RESULTS ARE DOCUMENTED IN MINUTES OF THE MEETINGS. |
| PUBLIC DISCLOSURE | FORM 990, PART VI, SECTION C, QUESTION 19 THE ORGANIZATION'S FORM 990 IS AVAILABLE ON WWW.GUIDESTAR.ORG AND ON THE ORGANIZATION'S PUBLIC WEBSITE WWW.JAX.ORG. THE ORGANIZATION'S FINANCIAL STATEMENTS AND CONFLICT OF INTEREST POLICY IS ALSO AVAILABLE AT WWW.JAX.ORG. THE GOVERNING DOCUMENTS ARE MADE AVAILABLE TO THE PUBLIC UPON REQUEST. |
| OFFICERS & KEY EMPLOYEES | PART VII THE LABORATORY DISCLOSES COMPENSATION INFORMATION FOR OFFICERS WITH DECISION-MAKING AND BUDGET AUTHORITY PURSUANT TO THE CORPORATIONS BYLAWS AND BOARD RESOLUTIONS. THE LABORATORY ALSO DISCLOSES KEY EMPLOYEES THAT MEET THE RESPONSIBILITY TEST AND COMPENSATION REPORTING THRESHOLD PURSUANT TO THE INSTRUCTIONS OF THE FORM 990. DURING 2015, THE LABORATORY CONDUCTED FURTHER ANALYSIS OF ITS OFFICERS AND KEY EMPLOYEES AND DETERMINED CERTAIN INDIVIDUALS DID NOT MEET THE REPORTING CRITERIA. INDIVIDUALS WHO DID NOT MEET THE REPORTING CRITERIA WERE REMOVED FROM THE FORM 990 FOR TAX YEAR 2015. THE INDIVIDUALS THAT WERE REMOVED FROM THE RETURN WERE ALSO NOT INCLUDED AS "FORMER" OFFICERS OR KEY EMPLOYEES FOR 2015 SINCE THEY WERE DETERMINED TO NOT ORIGINALLY MEET THE REQUISITE CRITERIA. THE LABORATORY STRIVES FOR TRANSPARENT REPORTING AS DEMONSTRATED BY MAKING ITS FORM 990 AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC ON ITS WEBSITE AS WELL AS FOR FULL COMPLIANCE WITH ALL TAX REPORTING REQUIREMENTS. SECURED MORTGAGES AND NOTES PAYABLE FORM 990, PART X, LINE 23 REPAYMENT TERMS: THE CT INNOVATIONS LOANS WILL BE FORGIVEN IF AND WHEN THE LABORATORY MEETS AN EMPLOYMENT GOAL OF AT LEAST 300 EMPLOYEES LOCATED IN CONNECTICUT FOR A PERIOD OF SIX MONTHS, INCLUDING A MINIMUM OF 90 SENIOR SCIENTISTS. IN ADDITION, THE AVERAGE WAGE FOR SUCH EMPLOYEES MUST EXCEED A MINIMUM TARGET LEVEL. |
| OTHER CHANGES IN NET ASSETS | FORM 990, PART XI, LINE 9 UNREALIZED GAIN ON INTEREST RATE SWAPS 355,476 CHANGES IN ACTUARIAL ASSUMPTIONS 489,890 FAIR MARKET VALUE ADJUSTMENT ON LOANS 75,936,130 TOTAL 76,781,496 |
| Software ID: | |
| Software Version: |